AI assistant
Oramed Pharmaceuticals Inc. — Director's Dealing 2025
Feb 11, 2025
6965_dirs_2025-02-11_c8586e9e-c371-4f6a-807a-52498dafdaee.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2025-02-11
Reporting Person: KIDRON NADAV (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-02-11 | Common Stock | A | 141000 | — | Acquired | 2400598 | Direct |
| 2025-02-11 | Common Stock | A | 186000 | — | Acquired | 2586598 | Direct |
| 2025-02-11 | Common Stock | A | 100000 | — | Acquired | 2686598 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 126000 | Indirect |
Footnotes
F1: Represents shares issued on settlement of performance stock units ("PSUs") previously granted on January 4, 2024 that vested on February 11, 2025 based on the achievement of the applicable performance criteria.
F2: Represents shares issued on settlement of PSUs previously granted on January 2, 2025 that vested on February 11, 2025 based on the achievement of the applicable performance criteria.
F3: Represents shares issued on settlement of PSUs previously granted on February 3, 2025 that vested on February 11, 2025 based on the achievement of the applicable performance criteria.